Publications by authors named "I N Micallef"
Cancer treatments have continued to improve tremendously over the past decade, but therapy resistance is still a common, major factor encountered by patients diagnosed with cancer. Chemoresistance arises due to various circumstances and among these causes, increasing evidence has shown that enzymes referred to as protein methyltransferases (PMTs) play a significant role in the development of chemoresistance in various cancers. These enzymes are responsible for the methylation of different amino acids, particularly lysine and arginine, via protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs), respectively.
View Article and Find Full Text PDFArticle Synopsis
- Crystal-storing histiocytosis (CSH) is a rare condition where abnormal protein crystals accumulate in the body, and when it affects the CNS, it can cause persistent imaging abnormalities.* -
- The study describes one local case of CNS CSH alongside 10 other cases, noting that 9 had brain parenchyma involvement and some cases were linked to conditions like lymphoma.* -
- While CNS CSH is uncommon, comprehensive evaluation for related malignancies is crucial, and treatment focuses on addressing these underlying conditions.*
Background And Objectives: Neurolymphomatosis (NL) is characterized by lymphomatous infiltration of the peripheral nervous system presenting as the initial manifestation of a lymphoma (primary NL [PNL]) or in relapse of a known lymphoma (secondary NL [SNL]). This report details and compares the neurologic clinicopathologic characteristics of these 2 groups.
Methods: This retrospective study was performed on patients diagnosed with pathologically confirmed NL in nerve between January 1, 1992, and June 31, 2020.
The infusion autograft absolute number of inhibitory killer immunoglobulin-like receptor (KIR) 2DL2 and activating natural killer (NK)p30 cells are predictors of clinical outcomes in lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). To assess if the long-term recovery of these NK cell subsets still holds clinical relevance, we set up to investigate their prognostic ability at day 100 post-APBHSCT. This was a retrospective single-institution study including 107 patients from our prior phase III trial who had a clinical assessment at day 100 post-APBHSCT.
View Article and Find Full Text PDFArticle Synopsis
- The standard treatment for fit patients with relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by autologous stem cell transplant (ASCT), but it may not be ideal for everyone.
- A study of 151 patients showed that while most had good responses before ASCT, those who had multiple lines of salvage chemotherapy or were diagnosed at an advanced stage faced significantly worse outcomes.
- Median progression-free survival was 54.5 months and overall survival was 88.9 months, with no significant survival difference based on age or other characteristics, although advanced-stage relapse and multiple salvage treatments negatively affected survival rates.